Browse > Article
http://dx.doi.org/10.3344/kjp.2011.24.3.164

Obturator Nerve Block with Botulinum Toxin Type B for Patient with Adductor Thigh Muscle Spasm -A Case Report-  

Choi, Eun-Joo (Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital)
Byun, Jong-Min (Seoul National University College of Medicine)
Nahm, Francis Sahng-Un (Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital)
Lee, Pyung-Bok (Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital)
Publication Information
The Korean Journal of Pain / v.24, no.3, 2011 , pp. 164-168 More about this Journal
Abstract
Obturator nerve block has been commonly used for pain management to prevent involuntary reflex of the adductor thigh muscles. One of several options for this block is chemical neurolysis. Neurolysis is done with chemical agents. Chemical agents used in the neurolysis of the obturator nerve have been alcohol, phenol, and botulinum toxin. In the current case, a patient with spasticity of the adductor thigh muscle due to cervical cord injury had obturator nerve neurolysis done with botulinum toxin type B (BoNT-B). Most of the previous studies have used BoNT-A with only a few reports that have used BoNT-B. BoNT-B has several advantages and disadvantages over BoNT-A. Thus, we report herein a patient who successfully received obturator nerve neurolysis using BoNT-B to treat adductor thigh muscle spasm.
Keywords
botulinum toxin type B; obturator nerve; spasticity;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Callaway JE, Arezzo JC, Grethlein AJ. Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology. Semin Cutan Med Surg 2001; 20: 127-36.   DOI
2 Ward A, Roberts G, Warner J, Gillard S. Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity. J Rehabil Med 2005; 37: 252-7.   DOI   ScienceOn
3 Factor SA, Molho ES, Evans S, Feustel PJ. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. Mov Disord 2005; 20: 1152-60.   DOI   ScienceOn
4 Callaway JE. Botulinum toxin type B (Myobloc): pharmacology and biochemistry. Clin Dermatol 2004; 22: 23-8.
5 Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994; 9: 213-7.
6 Akkaya T, Unlu E, Alptekin A, Gumus HI, Umay E, Cakci A. Neurolytic phenol blockade of the obturator nerve for severe adductor spasticity. Acta Anaesthesiol Scand 2010; 54: 79-85.   DOI   ScienceOn
7 Al-Saleem FH, Ancharski DM, Ravichandran E, Joshi SG, Singh AK, Gong Y, et al. The role of systemic handling in the pathophysiologic actions of botulinum toxin. J Pharmacol Exp Ther 2008; 326: 856-63.   DOI   ScienceOn
8 Figgitt DP, Noble S. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia. Drugs 2002; 62: 705-22.   DOI   ScienceOn
9 Aoki KR. Pharmacology and immunology of botulinum toxin type A. Clin Dermatol 2003; 21: 476-80.   DOI   ScienceOn
10 Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005; 65: 1423-9.   DOI   ScienceOn
11 Kharkar S, Ambady P, Yedatore V, Schwartzman RJ. Intramuscular botulinum toxin A (BtxA) in complex regional pain syndrome. Pain Physician 2011; 14: 311-6.
12 Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87: 1044-9.   DOI
13 Truong DD, Stenner A, Reichel G. Current clinical applications of botulinum toxin. Curr Pharm Des 2009; 15: 3671-80.   DOI   ScienceOn
14 Grunfeld A, Murray CA, Solish N. Botulinum toxin for hyperhidrosis: a review. Am J Clin Dermatol 2009; 10: 87-102.   DOI   ScienceOn
15 Lim SJ, Park HJ, Lee SH, Moon DE. Ganglion impar block with botulinum toxin type a for chronic perineal pain -a case report-. Korean J Pain 2010; 23: 65-9.   DOI
16 Calderon-Gonzalez R, Calderon-Sepulveda RF. Clinical treatment (non surgical) of spasticity in cerebral palsy. Rev Neurol 2002; 34: 1-6.
17 O'Brien CF. Treatment of spasticity with botulinum toxin. Clin J Pain 2002; 18(6 Suppl): S182-90.   DOI
18 Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage 2004; 28: 140-75.   DOI   ScienceOn
19 Dressler D, Adib Saberi F. Botulinum toxin: mechanisms of action. Eur Neurol 2005; 53: 3-9.
20 Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964; 192: 540-2.